First medicine targeting BRCA mutations to show clinical benefit in adjuvant settingWILMINGTON, Del. (BUSINESS WIRE) AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significa.
Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021
LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer
New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4-8, 2021.
Overall survival (OS) data from the Phase 2 CodeBreaK 100 trial of LUMAKRAS™ (sotorasib), a potentially first-in-class KRAS
AstraZeneca : ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience
05/19/2021 | 05:06pm EDT
Send by mail :
Message :
Required fields
LYNPARZA is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer
CALQUENCE shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib
IMFINZI five-year data represent longest-ever survival reported in a Phase III immunotherapy trial in unresectable Stage III lung cancer
AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 4 to 8, 2021.
Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
New Study Demonstrates the Clinical Utility of Predicine Liquid Biopsy Assay to Detect Copy Number Loss in Prostate Cancer
Share Article
Results from the study using liquid biopsy to detect copy number variations (CNVs), especially PTEN copy number loss, are now published in JCO Precision Oncology.
With Predicine’s next-generation liquid biopsy platform to decipher genomic insights especially gene deletion, we are able to identify nearly half of prostate cancer patients that may benefit from targeted therapy. HAYWARD, Calif. (PRWEB) May 17, 2021 Predicine, Inc. today announced results from a prostate cancer liquid biopsy study evaluating the landscape of genomic alterations in 231 patients with metastatic castration-resistant prostate cancer (mCRPC) from US and Australian cohorts.